BTG Appoints Fulcrum Pharma as its Preferred Provider of Drug Development Services.Business Editors/Health/Medical Writers WEST CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--March 29, 2004 BTG BTG BIT (Built-In Test) Target Generator BTG Bridging the Gap BTG British Technology Group BtG Betreuungsgesetz (Germany) BTG Biomass Technology Group BV BTG Begbies Traynor Group (LSE LSE - Language Sensitive Editor : BGC BGC General Cable Corporation (stock symbol) BGC Billy Graham Center BGC Baptist General Conference (formerly Swedish Baptist Denomination) BGC Boys & Girls Club BGC Bubblegum Crisis ), the global intellectual property and technology commercialization company, announced today that it has appointed Fulcrum Pharma Development Ltd. (LSE: FUL), the independent drug development services company, as its preferred provider of preclinical and clinical development services in the therapeutic areas of Oncology and Ageing & Neuroscience. This appointment reflects another major step for BTG in implementing its strategy to enhance the value of selected pharmaceutical compounds in its portfolio by investing in their preclinical and/or clinical development prior to out-licensing. BTG has already contracted Fulcrum to provide development services for its clinical trial of BGC 9331 - a potential treatment for gastric and other cancers. This Phase I/II trial is ongoing. It is anticipated that the first programs performed under the preferred provider relationship will be: BGC 945 - a new and highly selective potential treatment for cancers that is designed to be much less toxic and better tolerated than conventional drugs; and BGC 20-1259 for the treatment for Alzheimer's Disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. . In the longer-term, BTG has a strong pipeline of early-stage pharmaceutical opportunities that may be candidates for further development prior to out-licensing. Anthony V. Lando, BTG's Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. , commented, "BTG is building a strong out-licensing portfolio of drugs in Oncology and Ageing & Neuroscience, and we are willing to back our judgment by investing in their development. Our relationship with Fulcrum gives BTG access to high quality drug development services." Jon Court, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Fulcrum Pharma, commented, "We are delighted to have been selected by BTG as their preferred provider of preclinical and clinical development services. BTG and Fulcrum have been successfully working together since 2002, and this agreement represents a broadening of this relationship. We look forward to supporting BTG as they build a strong portfolio of drugs for out-licensing." About BTG BTG finds, develops and commercializes emerging technologies in the life and physical sciences. These innovations are protected by a strong portfolio of intellectual property that BTG develops and enhances. BTG then captures the value in these technologies through licensing and venturing activities. From the origins of its business in 1949, BTG has commercialized major innovations such as Magnetic Resonance Imaging magnetic resonance imaging (MRI), noninvasive diagnostic technique that uses nuclear magnetic resonance to produce cross-sectional images of organs and other internal body structures. (MRI 1. (application) MRI - Magnetic Resonance Imaging. 2. MRI - Measurement Requirements and Interface. ), recombinant factor IX blood-clotting protein, Campath(R) (alemtuzumab) and Multilevel mul·ti·lev·el adj. Having several levels: a multilevel parking garage. Adj. 1. multilevel - of a building having more than one level Cell (MLC (MultiLevel Cell) A flash memory technology that stores more than one bit per cell. Traditional flash memory defines a 0 or 1 bit based on a single voltage threshold. ) memory. BTG is quoted on the London Stock Exchange London Stock Exchange London marketplace for securities. It was formed in 1773 by a group of stockbrokers who had been doing business informally in local coffeehouses. under the symbol "BGC" and operates from offices in London and Philadelphia, with representation in Tokyo. BTG operates through wholly owned subsidiaries, BTG International Ltd. and BTG International Inc. in the UK and USA, respectively. Further information on BTG can be found at www.btgplc.com. About Fulcrum Pharma Fulcrum Pharma plc is an independent, drug development company that is the first to offer global virtual drug development and strategic outsourcing services to the pharmaceutical industry. The company has expertise in the design, execution and delivery of drug development programs and relies on state of the art information technology and infrastructure in the supply of its services. Through Fulcrum's services to its clients, the Directors believe that there is the capacity to deliver products faster and more efficiently to the global pharmaceutical market. Fulcrum does this by using its skills in the design of drug programs that deliver the necessary information for decision-making and product registration. In so doing, Fulcrum works closely with its clients to meet their strategic R&D goals. Fulcrum Pharma is listed on the Alternative Investment Market of the London Stock Exchange having successfully floated in March 2000. Further information about Fulcrum Pharma can be found at www.fulcrumpharma.co.uk |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion